全球视角：天花疫苗预防猴痘的感染的有效性、保护性、安全性分析

[1] McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis. 2014 Jan;58(2):260–267.

[2] Daskalakis D, McClung RP, Mena L, et al. Monkeypox: avoiding the mistakes of past infectious disease epidemics. Ann Intern Med. 2022 Aug;175 (8):1177–1178.

[3] Gessain A, Nakoune E, Yazdanpanah Y. Monkeypox. N Engl J Med. 2022 Nov 10;387(19):1783–1793.

[4] Lourie B, Bingham PG, Evans HH, et al. Human infection with monkeypox virus: laboratory investigation of six cases in West Africa. Bull World Health Organ. 1972;46(5):633–639.

[5] Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ. 1972;46(5):593–597.

[6] Yinka-Ogunleye A, Aruna O, Dalhat M, et al. Outbreak of human monkeypox in Nigeria in 20172018: a clinical and epidemiological report. Lancet Infect Dis. 2019 Aug;19(8):872–879.

[7] Mauldin MR, McCollum AM, Nakazawa YJ, et al. Exportation of monkeypox virus from the African continent. J Infect Dis. 2022 Apr 19;225(8):13671376.

[8] 2022-24 Mpox Outbreak: Global Trends. Geneva: World Health Organization 2024 [cited 2024 Apr 25]. Available at https://worldhealthorg.shinyapps.io/mpx_global/.

[9] WHO Director-General declares the ongoing monkeypox outbreak a Public Health Emergency of International Concern.

[10] Mansour R, Houston A, Majeed A, et al. Human monkeypox: diagnosis and management. Br Med J. 2023 Feb 6;380:e073352.

[11] Chen N, Li G, Liszewski MK, et al. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology. 2005 Sep 15;340(1):46–63.

[12] Mitjà O, Alemany A, Marks M, et al. Mpox in people with advanced HIV infection: a global case series. Lancet. 2023 Mar 18;401(10380):939–949.

[13] Shchelkunov SN, Totmenin AV, Babkin IV, et al. Human monkeypox and smallpox viruses: genomic comparison. FEBS Lett. 2001 Nov 30;509(1):66–70.

[14] Dalton AF, Diallo AO, Chard AN, et al. Estimated effectiveness of JYNNEOS vaccine in preventing mpox: a multijurisdictional case-control study United States, August 19, 2022-March 31, 2023. MMWR Morb Mortal Wkly Rep. 2023 May 19;72 (20):553-558.

[15] Deputy NP, Deckert J, Chard AN, et al. Vaccine effectiveness of JYNNEOS against mpox disease in the United States [Article]. N Engl J Med. 2023 Jun 29;388(26):2434-2443.

[16] Wolff Sagy Y, Zucker R, Hammerman A, et al. Realworld effectiveness of a single dose of mpox vaccine in males. Nat Med. 2023 Mar;29(3):748–752.

[17] Rosenberg ES, Dorabawila V, Hart-Malloy R, et al. Effectiveness of JYNNEOS vaccine against diagnosed mpox infection - New York, 2022. MMWR Morb Mortal Wkly Rep. 2023 May 19;72(20):559–563.

[18] Ramchandani MS, Berzkalns A, Cannon CA, et al. Effectiveness of the modified vaccinia Ankara vaccine against mpox in men who have sex with men: a retrospective cohort analysis, Seattle, Washington. Open Forum Infect Dis. 2023 Nov;10(11):ofad528.

[19] Navarro C, Lau C, Buchan SA, et al. Effectiveness of one dose of MVA-BN vaccine against mpox infection in males in Ontario, Canada: a target trial emulation, 2023.

[20] Rosen JB, Arciuolo RJ, Pathela P, et al. JYNNEOS™ effectiveness as post-exposure prophylaxis against mpox: challenges using real-world outbreak data. Vaccine. 2024 Jan 25;42(3):548-555.

[21] Hens M, Brosius I, Berens-Riha N, et al. Characteristics of confirmed mpox cases among clinical suspects: a prospective single-centre study in Belgium during the 2022 outbreak. New Microbes New Infect. 2023 Mar;52:101093.

[22] Fontán-Vela M, Hernando V, Olmedo C, et al. Effectiveness of MVA-BN vaccination in a population at high-risk of mpox: a Spanish cohort study. Clin Infect Dis. 2024 Feb 17;78(2):476-483.

[23] Brousseau N, Carazo S, Febriani Y, et al. Single-dose effectiveness of mpox vaccine in Quebec, Canada: test-negative design with and without adjustment for self-reported exposure risk. Clin Infect Dis. 2024 Feb 17;78(2):461-469.

[24] Morales LM, del Buey JFB, García MA, et al. Postexposure vaccine effectiveness and contact management in the mpox outbreak, Madrid, Spain, May to August 2022. Eurosurveillance. 2023;28 (24):2200883.

[25] van Ewijk CE, Miura F, van Rijckevorsel G, et al. Monkeypox outbreak in the Netherlands in 2022: public health response, epidemiological and clinical characteristics of the first 1000 cases and protection of the first-generation smallpox vaccine. 2022.

[26] Karem KL, Reynolds M, Hughes C, et al. Monkey poxinduced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin Vaccine Immunol. 2007 Oct;14(10):1318-1327.

[27] Kalthan E, Tenguere J, Ndjapou SG, et al. Investigation of an outbreak of monkeypox in an area occupied by armed groups, Central African Republic. Med Mal Infect. 2018;48(4):263268.

[28] Schildhauer S, Saadeh K, Vance J, et al. Reduced odds of mpox-associated hospitalization among persons who received JYNNEOS vaccine-California, May 2022-May 2023. MMWR Recommendations Reports. 2023;72(36):992-996.

[29] van Ewijk CE, Miura F, van Rijckevorsel G, et al. Mpox outbreak in the Netherlands, 2022: public health response, characteristics of the first 1,000 cases and protection of the first-generation smallpox vaccine [Article]. Eurosurveillance. 2023 Mar 23;28(12):2200772.

[30] Farrar JL, Lewis NM, Houck K, et al. Demographic and clinical characteristics of mpox in persons who had previously received 1 dose of JYNNEOS vaccine and in unvaccinated persons-29 U.S. jurisdictions, May 22–September 3, 2022. Am J Transplant. 2023;23(2):298-303.

[31] Tomita N, Terada-Hirashima J, Uemura Y, et al. An open-label, non-randomized study investigating the safety and efficacy of smallpox vaccine, LC16, as post-exposure prophylaxis for mpox. Hum Vaccin Immunother. 2023 Aug 1;19(2):2242219.

[32] Montalti M, Di Valerio Z, Angelini R, et al. Safety of monkeypox vaccine using active surveillance, two-center observational study in Italy. Vaccines (Basel). 2023 Jun 27;11(7):1163.

[33] Lee J, Kwon SL, Park J, et al. JYNNEOS vaccine safety monitoring in the Republic of Korea, 2022: a cross-sectional study. Osong Public Health Res Perspect. 2023 Oct;14(5):433-438.

[34] Duffy J, Marquez P, Moro P, et al. Safety monitoring of JYNNEOS vaccine during the 2022 mpox outbreak United States, May 22-October 21, 2022. Morb Mortal Wkly Rep. 2022;71(49):1555-1559.

[35] Deng L, Lopez LK, Glover C, et al. Short-term adverse events following immunization with Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine for mpox. Jama. 2023 Jun 20;329(23):2091-2094.

[36] Lim SY, Jung YM, Kim Y, et al. Adverse reactions after intradermal vaccination with JYNNEOS for mpox in Korea. J Korean Med Sci. 2024 Mar 4;39(8):e100.

[37] Swift MD, McDermott MC, Hainy CM, et al. Early experience with an occupational JYNNEOS (Orthopoxvirus) vaccination program. J Occup Environ Med. 2023 Jun 1;65(6):477-480.

[38] Mazzotta V, Lepri AC, Matusali G, et al. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study. E Clinical Medicine. 2024 Feb;68:102420.

[39] Petersen BW, Kabamba J, McCollum AM, et al. Vaccinating against monkeypox in the Democratic Republic of the Congo. Antiviral Res. 2019 Feb;162:171-177.

[40] Sah R, Paul D, Mohanty A, et al. Monkeypox (mpox) vaccines and their side effects: the other side of the coin. Int J Surg. 2023 Feb 1;109(2):215-217.

[41] Artenstein AW. New generation smallpox vaccines: a review of preclinical and clinical data. Rev Med Virol. 2008 Jul-Aug;18(4):217-231.